These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J; Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073 [TBL] [Abstract][Full Text] [Related]
30. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667 [TBL] [Abstract][Full Text] [Related]
31. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090 [TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL; Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562 [TBL] [Abstract][Full Text] [Related]
33. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J; Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005 [TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831 [TBL] [Abstract][Full Text] [Related]
35. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Kawazoe A; Fukuoka S; Nakamura Y; Kuboki Y; Wakabayashi M; Nomura S; Mikamoto Y; Shima H; Fujishiro N; Higuchi T; Sato A; Kuwata T; Shitara K Lancet Oncol; 2020 Aug; 21(8):1057-1065. PubMed ID: 32589866 [TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113 [TBL] [Abstract][Full Text] [Related]
37. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653 [TBL] [Abstract][Full Text] [Related]
38. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288 [TBL] [Abstract][Full Text] [Related]
39. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L; Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820 [TBL] [Abstract][Full Text] [Related]
40. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]